What Is Humanin Peptide? The Mitochondrial-Derived Research Compound Guide (2026)
In 2001, a research group studying Alzheimer’s disease genetics made an unexpected discovery. They were examining brain tissue from a patient who carried known genetic risk factors for the disease but had never developed it. Inside that tissue, a small peptide was being expressed that appeared to protect neurons from the very toxins associated with amyloid-beta pathology. That peptide was Humanin.
The name came from the researchers’ intuition that they had found something genuinely protective — something that held the cell together under conditions that would otherwise trigger its death. Over the two decades since that initial discovery, the research has expanded considerably. What started as a neuroprotection story has grown into a broader investigation into how a peptide encoded within mitochondrial DNA communicates with the rest of the cell, how its levels relate to aging and longevity across multiple species, and what its interactions with the growth hormone and IGF-1 axis tell us about the biology of aging at a molecular level.
What Humanin Is
Humanin is a short peptide encoded within the 16S ribosomal RNA gene of mitochondrial DNA. Its length depends on where it is synthesized — 21 amino acids when produced inside the mitochondria, 24 amino acids when produced in the cytosol. Both forms are biologically active in published research.
The mitochondrial origin is the detail that makes Humanin scientifically distinctive. The human mitochondrial genome is ancient — roughly 1.5 billion years old, inherited from the alpha-proteobacterium that became the first mitochondrion. It encodes only 37 genes and was long considered primarily structural. The discovery that it encodes functional signaling peptides like Humanin revised that assumption fundamentally and gave rise to the category of compounds now called mitochondrial-derived peptides (MDPs). Humanin was the first characterized member of this family. MOTS-C, the other well-studied MDP carried in the Patriot Peptides catalog, was characterized later.
Because Humanin is encoded in mitochondrial DNA and its production levels respond to metabolic state and cellular stress, researchers have described it as a metabolic stress sensor whose output happens to be cytoprotective. It is not simply a neuroprotective compound that happens to be produced in mitochondria — it is part of the mitochondrial signaling system that communicates cellular status to the broader organism, and its cytoprotective activity is a downstream consequence of that signaling function.
Compound specifications:
| Property | Detail |
|---|---|
| Common name | Humanin |
| Also known as | HN, MTRNR2 peptide |
| Amino acids | 21 (mitochondrial synthesis) or 24 (cytosolic synthesis) |
| Molecular formula | C119H204N34O32S2 |
| Molecular weight | ~2,687.3 g/mol |
| Genome origin | Mitochondrial 16S rRNA gene |
| Receptor pathways | FPRL1/FPR2, gp130 complex |
| Downstream signaling | STAT3, AKT, ERK1/2 |
| Supplied form | Lyophilized powder |
| Vial size | 10mg |
| Storage lyophilized | -20°C up to 24 months |
| Storage reconstituted | 2-8°C up to 28 days |
How Humanin Works — The Mechanisms
Humanin’s receptor biology is more complex than most research peptides. Its activity runs through two primary receptor systems — FPRL1/FPR2 and the gp130 receptor complex — which engage downstream signaling pathways with broad consequences for cell survival and inflammatory regulation.
The gp130 receptor complex, shared with cytokines in the IL-6 family, activates STAT3 and AKT signaling when engaged by Humanin. STAT3 drives transcription of survival genes and suppresses pro-apoptotic programs. AKT is one of the primary kinases in the PI3K/AKT cell survival pathway, promoting cell survival and suppressing apoptosis through multiple downstream targets. ERK1/2 activation adds a second survival-promoting signal through the MAPK pathway. These three downstream pathways — STAT3, AKT, and ERK1/2 — all converge on the same outcome: suppression of programmed cell death and promotion of cellular survival under stress conditions.
The anti-apoptotic mechanism operates through direct interactions with specific intracellular targets. Humanin interacts with IGFBP3 — insulin-like growth factor binding protein 3 — neutralizing its pro-apoptotic activity. IGFBP3 normally acts as a carrier for IGF-1 in the bloodstream but also has nuclear functions related to apoptosis promotion. Humanin’s binding reduces this apoptotic pressure. Humanin also interacts directly with Bax — a pro-apoptotic Bcl-2 family member that initiates the intrinsic apoptotic cascade by permeabilizing the outer mitochondrial membrane. By sequestering Bax, Humanin prevents the release of cytochrome c from mitochondria that would otherwise trigger cell death.
This combination — receptor-mediated activation of survival pathways and direct inhibition of apoptotic effectors — gives Humanin a multi-layered cytoprotective profile that operates through convergent mechanisms rather than a single intervention point.
The Aging and Longevity Connection
The relationship between Humanin levels and aging is one of the most consistently replicated findings in the research literature on this compound, and it’s worth examining in detail because it forms the foundation of most of the scientific interest in Humanin from a longevity research perspective.
Circulating Humanin levels decline with age in both mice and humans. Multiple research groups have documented this decline across different model systems, and the pattern is consistent enough that Humanin has been described as an aging biomarker — a molecule whose declining levels reflect the biological changes associated with aging rather than simply correlating with them.
The relationship with the growth hormone and IGF-1 axis is particularly informative. Long-lived Ames dwarf mice — which are deficient in growth hormone — have Humanin levels approximately 50% higher than normal controls. Short-lived GH-transgenic mice, which have chronically elevated GH and IGF-1, have significantly reduced Humanin levels. Administration of growth hormone or IGF-1 to both mice and human subjects reduced circulating Humanin levels, establishing a causal direction for this relationship: higher GH/IGF-1 activity suppresses Humanin production.
This inverse relationship is significant because the GH/IGF-1 axis is one of the most studied determinants of lifespan in model organisms. Multiple species with mutations that reduce GH/IGF-1 signaling show extended lifespan. The Ames dwarf mouse data showing that reduced GH/IGF-1 activity correlates with both higher Humanin levels and longer lifespan raised the research question of whether Humanin mediates some of the longevity benefits associated with reduced GH/IGF-1 activity.
A pivotal 2020 paper published in Aging (Yen et al., DOI: 10.18632/aging.103534) provided direct evidence for this connection. The study showed that in C. elegans, overexpression of Humanin is sufficient to increase lifespan, dependent on daf-16/Foxo — the worm homolog of the FOXO transcription factor that is central to insulin/IGF-1-mediated longevity regulation. Humanin transgenic mice showed overlapping phenotypes with the worm data. Treatment of middle-aged mice twice weekly with the potent Humanin analogue HNG improved metabolic healthspan parameters and reduced inflammatory markers. Critically, the study examined Humanin levels in naked mole-rats — animals with negligible senescence that live approximately ten times longer than similarly sized rodents — and found that their Humanin levels remain surprisingly stable with age, in contrast to the declining levels seen in normal mice and humans.
What the Research Shows — By Tissue and System
Neurological Research
Humanin’s first identified function was neuroprotection against amyloid-beta toxicity, and the neurological research base remains its most extensive. In cell culture models, Humanin protects neurons against multiple neurotoxic insults including amyloid-beta peptide aggregates, oxidative stress, and glutamate excitotoxicity. The proposed mechanisms involve the survival pathways already described — STAT3, AKT, and Bax inhibition — acting on neural tissue specifically.
Age-dependent differences in Humanin’s signaling responses have been documented in hippocampal tissue specifically. The hippocampus is the brain region most associated with memory formation and most vulnerable to early Alzheimer’s pathology, and the observation that Humanin signaling behaves differently in aged versus young hippocampal tissue has informed research on whether declining Humanin levels contribute to the increased vulnerability of aged neural tissue to degenerative processes.
Research has also examined Humanin in stroke and ischemia models, where its cytoprotective mechanisms — particularly Bax inhibition and mitochondrial membrane stabilization — are mechanistically relevant to the cell death pathways activated by ischemic injury.
Metabolic Research
The connection between Humanin and insulin signaling has driven significant research interest in its metabolic applications. Through its interactions with IGFBP3, Humanin modulates IGF-1 availability and signaling, which has direct implications for insulin sensitivity research. Studies in insulin resistance models have shown Humanin improving glucose tolerance and insulin sensitivity in preclinical systems, consistent with the broader relationship between the IGF-1 axis and metabolic function.
The 2020 Yen et al. paper documented improvements in metabolic healthspan parameters in middle-aged mice treated with the Humanin analogue HNG, providing evidence that Humanin’s metabolic effects are accessible through exogenous administration rather than only reflecting endogenous production levels.
Cardiovascular Research
Multiple research groups have examined Humanin in cardiovascular models, particularly in the context of atherosclerosis and cardiac ischemia. Its anti-apoptotic and anti-inflammatory mechanisms are directly relevant in vascular biology, where endothelial cell death and smooth muscle cell apoptosis contribute to plaque development and instability. Research has documented Humanin reducing markers of cardiovascular aging risk in preclinical models, and its interactions with the GH/IGF-1 axis are relevant in the context of the metabolic risk factors associated with cardiovascular disease.
Ocular Research
Humanin has appeared in research examining retinal pigment epithelial cells — the cell type that degenerates in age-related macular degeneration. Studies have shown Humanin restoring mitochondrial bioenergetics and improving mitochondrial function in these cells, with implications for research into the mitochondrial contributions to AMD pathology. The ocular research base is smaller than the neurological literature but represents an emerging application area driven by the same cytoprotective mechanisms documented elsewhere.
Humanin and MOTS-C — Related but Distinct
Humanin and MOTS-C are both mitochondrial-derived peptides — both encoded in mitochondrial DNA, both studied in longevity and aging biology contexts — but their mechanisms and primary research applications are distinct in ways that matter for research design.
MOTS-C is a 16-amino acid peptide encoded in the mitochondrial 12S rRNA gene. Its primary mechanism involves AMPK pathway activation and regulation of cellular energy metabolism. Its most studied research applications are metabolic — insulin sensitivity, energy expenditure, exercise biology. It functions as what researchers have described as an exercise mimetic, activating metabolic programs that normally require physical activity.
Humanin’s primary mechanisms are cytoprotective and anti-apoptotic — protecting cells from stress-induced death through STAT3, AKT, and Bax inhibition. Its most studied applications are neurological and longevity-related rather than primarily metabolic. Where MOTS-C’s research is centered on energy regulation, Humanin’s research is centered on cell survival under aging-associated stress conditions.
They are sometimes studied together precisely because they address different biological questions from within the same MDP family — providing complementary tools for research examining how mitochondrial signaling contributes to both metabolic function and cellular longevity through distinct pathways.
Quality Standards for Research Use
Humanin research requires the same four-point quality verification that applies to all serious research peptide work. HPLC purity analysis confirming the compound constitutes at least 99% of the sample. Mass spectrometry identity verification confirming molecular weight and fragmentation pattern match Humanin’s known profile. Endotoxin screening — particularly important in cell-based research examining apoptotic and inflammatory pathways, where endotoxin contamination would directly confound the outcomes being measured. Sterility testing confirming absence of microbial contamination.
All Patriot Peptides Humanin (10mg) is manufactured in a cGMP-certified US facility and independently tested by a certified third-party laboratory across all four criteria. Batch-specific Certificates of Analysis are available. For laboratory research use only.
Frequently Asked Questions
What is Humanin peptide? Humanin is a naturally occurring peptide encoded within the mitochondrial 16S rRNA gene — making it a mitochondrial-derived peptide (MDP) produced by mitochondrial DNA rather than nuclear DNA. It was first identified in 2001 as a neuroprotective molecule and has since been studied across multiple research contexts including apoptosis regulation, aging biology, metabolic research, and neuroprotection. It is available in research-grade lyophilized form for controlled laboratory investigation.
How does Humanin work? Humanin signals through FPRL1/FPR2 and gp130 receptor complexes, activating STAT3, AKT, and ERK1/2 survival pathways. It directly inhibits pro-apoptotic proteins including IGFBP3 and Bax, preventing the intrinsic apoptotic cascade from initiating. The combined effect is multi-layered cytoprotection that operates through convergent survival mechanisms rather than a single pathway.
What is the difference between Humanin and MOTS-C? Both are mitochondrial-derived peptides encoded in mitochondrial DNA. Humanin operates primarily through cytoprotective and anti-apoptotic mechanisms with main research applications in neuroprotection, aging biology, and cardiovascular research. MOTS-C operates primarily through AMPK-mediated metabolic regulation with main applications in metabolic and exercise biology research. They address different biological questions within the same MDP family.
What does the longevity research on Humanin show? Humanin levels decline with age in both mice and humans. Long-lived animal models show higher Humanin levels; shorter-lived GH-transgenic models show lower levels. The 2020 Yen et al. study in Aging demonstrated that Humanin overexpression is sufficient to extend lifespan in C. elegans through daf-16/Foxo-dependent mechanisms, and that treatment of middle-aged mice with a Humanin analogue improved metabolic healthspan markers and reduced inflammatory parameters.
Is Humanin FDA-approved? No. Humanin is not FDA-approved for any therapeutic indication. It is a research compound studied in preclinical and early laboratory contexts, available for legitimate laboratory research use only.
Where can I buy research-grade Humanin? Patriot Peptides Humanin (10mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility. Batch-specific Certificates of Analysis available. For laboratory research use only.
All content is for informational and educational purposes only. All Patriot Peptides products are strictly for laboratory research use only. Not for human consumption, veterinary use, or clinical application.
Related reading: What Is MOTS-C? | What Are Research Peptides? | How to Store Lyophilized Peptides